Male subjects who are unwilling to use acceptable method of effective contraception.
Acceptable method of contraception
Male subjects must agree to use an acceptable method of contraception beginning prior to study entry, for the duration of the study, and for six months following last dose of avelumab/utomilumab
Male subjects must agree to use an acceptable method of contraception beginning prior to study entry, for the duration of the study, and for six months following duration of study participation
Male subject agrees to use an acceptable method of contraception for the duration of the study
Male subject agrees to use an acceptable method of contraception for the duration of the study
Male patient agrees to use an adequate method of contraception for the duration of the study
Male patient agrees to use an adequate method of contraception
Agrees to follow protocol-defined method(s) of contraception
AMKL PATIENTS: Male patients, even if surgically sterilized (i.e. status post-vasectomy) agrees to use an acceptable method for contraception during the entire study treatment period through  days after the last dose of alisertib; likewise, female patients should agree to use acceptable method for contraception during the entire study treatment period through  days after the last dose of alisertib
MF PATIENTS: Male patients, even if surgically sterilized (i.e. status post-vasectomy) agrees to use an acceptable method for contraception during the entire study treatment period through  days after the last dose of alisertib; likewise, female patients should agree to use acceptable method for contraception during the entire study treatment period through  days after the last dose of alisertib
Male subject unwilling to use an acceptable method for contraception for the duration of the study and one year beyond treatment completion, will not be eligible to participate in the study
Male subject agrees to use an acceptable method for contraception during the entire study treatment period and through  months after the last dose of brentuximab vedotin
Women of childbearing potential and male participants who are unwilling or unable to use an acceptable method of contraception throughout the study and for four weeks after completion of treatment or those who are using a prohibited contraceptive method
Male subject agrees to use an acceptable method for contraception for the duration of the study
Subject agrees to use adequate contraception during the study period and for  weeks after last dose of study therapy
Male subject agrees to use an acceptable method for contraception during the entire study treatment period and through  months after the last dose of lenalidomide
Male subject agrees to use an acceptable method for contraception for the duration of the study
Male subject agrees to use an acceptable method for contraception for the duration of the study
Male subject agrees to use an acceptable method for contraception for the duration of the study.
Male subject agrees to use an acceptable method for contraception for the duration of the study
Male subject unwilling to use an acceptable method for contraception for the duration of the study and one year beyond treatment completion
Male subject agrees to use an acceptable method for contraception during the entire study treatment period through  months after the last dose of MLN
Male subject agrees to use an acceptable method for contraception for the duration of the study
Male subject agrees to use an acceptable method of contraception for the duration of the study
Male participants must agree to use an acceptable method for contraception during the entire study treatment period and through  months after the last dose of treatment
Agrees to use an adequate method of contraception during the study and until  months after the last treatment.
